Abbott Laboratories (ABT) Peer Comparison
$103.50
As on 27-Oct-2026 14:44EDT
Market cap
$179,441 Mln
Revenue (TTM)
$48,229 Mln
P/E Ratio
38.6
P/B Ratio
3.6
Div. Yield
2.5 %
| Abbott Laboratories (ABT) | Thermo Fisher Scientific (TMO) | Danaher (DHR) | Intuitive Surgical (ISRG) | Integra LifeSciences Holdings (IART) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
179,441 | 250,149 | 161,511 | 159,784 | 926 |
Revenue ($ Mln) |
48,229 | 47,351 | 25,608 | 11,578 | 1,657 |
Net Profit ($ Mln) |
4,701.00 | 7,083.00 | 4,331.00 | 2,957.20 | 13.01 |
Net Margin (%) |
9.75 | 14.96 | 16.91 | 25.54 | 0.79 |
RoE (%) |
18.06 | 13.25 | 8.13 | 17.59 | 1.23 |
Price to Earnings |
38.55 | 36.61 | 38.04 | 54.69 | 70.06 |
Price-To-Book |
3.58 | 4.67 | 2.96 | 7.82 | 1.19 |
Income Statement ($ Mln)
| Abbott Laboratories (ABT) | Thermo Fisher Scientific (TMO) | Danaher (DHR) | Intuitive Surgical (ISRG) | Integra LifeSciences Holdings (IART) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
48,229.00 | 47,351.00 | 25,608.00 | 11,578.00 | 1,656.79 |
|
Cost of Revenue
|
20,681.00 | 27,729.00 | 10,603.00 | 3,798.50 | 787.58 |
|
Gross Profit
|
24,607.00 | 18,239.00 | 14,970.00 | 6,642.30 | 845.23 |
|
Operating Expenses
|
20,197.00 | 11,106.00 | 9,787.00 | 4,495.40 | 234.74 |
|
Operating Profit (EBIT)
|
7,351.00 | 8,515.00 | 5,218.00 | 3,284.10 | 634.47 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
6,562.00 | 7,869.00 | 4,818.00 | 3,619.00 | 22.31 |
|
Provision for Tax
|
1,861.00 | 742.00 | 487.00 | 645.90 | 9.30 |
|
Profit after Tax (Net Income)
|
4,701.00 | 7,083.00 | 4,331.00 | 2,957.20 | 13.01 |
|
Minority Interest
|
0.00 | -16.00 | 0.00 | -14.30 | 0.00 |
|
Consolidated Profit
|
1,776.00 | 1,964.00 | 1,197.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Abbott Laboratories (ABT) | Thermo Fisher Scientific (TMO) | Danaher (DHR) | Intuitive Surgical (ISRG) | Integra LifeSciences Holdings (IART) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
0.00 | 54,767.00 | 53,621.00 | 15,986.20 | 1,066.62 |
|
Minority Interest
|
0.00 | -16.00 | 0.00 | -14.30 | 0.00 |
|
Non-Current Liabilities
|
0.00 | 45,296.00 | 30,610.00 | 698.30 | 2,112.18 |
|
Current Liabilities
|
0.00 | 14,170.00 | 9,050.00 | 2,533.00 | 329.00 |
|
Total Liabilities
|
86,713.00 | 110,343.00 | 83,464.00 | 20,631.20 | 3,602.00 |
Assets ($ Mln)
| Abbott Laboratories (ABT) | Thermo Fisher Scientific (TMO) | Danaher (DHR) | Intuitive Surgical (ISRG) | Integra LifeSciences Holdings (IART) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.00 | 88,618.00 | 78,494.00 | 10,920.80 | 2,317.86 |
|
Current Assets
|
0.00 | 25,615.00 | 14,787.00 | 8,428.30 | 1,189.94 |
|
Total Assets
|
86,713.00 | 110,343.00 | 83,464.00 | 20,631.20 | 3,602.00 |
|
Total Debt*
|
0.00 | 41,370.00 | 26,482.00 | 0.00 | 2,002.27 |
|
Net Current Assets
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cashflow ($ Mln)
| Abbott Laboratories (ABT) | Thermo Fisher Scientific (TMO) | Danaher (DHR) | Intuitive Surgical (ISRG) | Integra LifeSciences Holdings (IART) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
9,566.00 | 7,818.00 | 6,416.00 | 3,030.50 | 50.38 |
|
Cash Flow from Investing Activities
|
-2,422.00 | -4,047.00 | -1,196.00 | 665.80 | -108.06 |
|
Cash from Financing Activities
|
-6,309.00 | 1,801.00 | -2,961.00 | -2,364.10 | 28.34 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Abbott Laboratories (ABT) | Thermo Fisher Scientific (TMO) | Danaher (DHR) | Intuitive Surgical (ISRG) | Integra LifeSciences Holdings (IART) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
10.03 | 7.69 | 5.25 | 16.46 | -15.64 |
|
ROE (%)
|
18.06 | 13.25 | 8.13 | 17.59 | 1.23 |
|
ROA (%)
|
9.52 | 5.50 | 4.46 | 12.09 | 0.30 |
|
EBIT Margin (%)
|
11.82 | 13.63 | 15.27 | 24.79 | 4.84 |
|
Net Margin (%)
|
9.75 | 14.96 | 16.91 | 25.54 | 0.79 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Abbott Laboratories (ABT) | Thermo Fisher Scientific (TMO) | Danaher (DHR) | Intuitive Surgical (ISRG) | Integra LifeSciences Holdings (IART) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
10.00 | 8.27 | 5.52 | 20.45 | 0.84 |
|
EBIT Growth (%)
|
-34.24 | -24.37 | -12.03 | -9.33 | 117.29 |
|
Net Profit Growth (%)
|
-66.37 | 7.81 | 23.64 | 7.66 | 102.63 |
|
EPS Growth (%)
|
-66.31 | 9.68 | 26.16 | 9.30 | 102.53 |
|
Book Value Growth (%)
|
-- | 9.37 | 6.02 | -2.83 | 0.41 |
Valuation Ratios
| Abbott Laboratories (ABT) | Thermo Fisher Scientific (TMO) | Danaher (DHR) | Intuitive Surgical (ISRG) | Integra LifeSciences Holdings (IART) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
33.55 | 32.43 | 45.04 | 71.47 | -1.85 |
|
Price / Book Value
|
4.20 | 4.09 | 3.10 | 11.45 | 0.91 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
18.87 | 21.61 | 25.42 | 49.76 | -8.37 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Abbott Laboratories (ABT) | Thermo Fisher Scientific (TMO) | Danaher (DHR) | Intuitive Surgical (ISRG) | Integra LifeSciences Holdings (IART) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.29 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
0.06 | 0.04 | 0.04 | 0.00 | 0.06 |
|
Current Ratio
|
1.58 | 1.81 | 1.63 | 3.33 | 3.62 |
|
Quick Ratio
|
1.18 | 1.41 | 1.29 | 2.49 | 2.21 |
|
Interest Coverage
|
8.37 | 6.12 | 14.38 | -- | 1.23 |
Operating Efficiency Ratios
| Abbott Laboratories (ABT) | Thermo Fisher Scientific (TMO) | Danaher (DHR) | Intuitive Surgical (ISRG) | Integra LifeSciences Holdings (IART) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
0.00 | 20.33 | 20.02 | 14.87 | 15.03 |
|
Asset Turnover
|
0.98 | 0.37 | 0.26 | 0.47 | 0.38 |
|
Receivable days
|
61.20 | 82.76 | 61.72 | 54.16 | 61.56 |
|
Inventory Days
|
117.44 | 72.19 | 91.69 | 177.54 | 213.10 |
|
Payable days
|
78.11 | 46.50 | 68.44 | 23.93 | 41.20 |
|
Cash Conversion Cycle
|
100.53 | 108.45 | 84.97 | 207.78 | 233.46 |